- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/62 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 213/62
Total number of patents in this class: 108
10-year publication summary
|
3
|
5
|
2
|
5
|
5
|
4
|
3
|
1
|
8
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4642 |
6 |
| Akebia Therapeutics, Inc. | 114 |
6 |
| Bristol-myers Squibb Company | 4880 |
5 |
| Nippon Soda Co., Ltd. | 895 |
4 |
| Amygdala Neurosciences, Inc. | 19 |
4 |
| Dow AgroSciences LLC | 1223 |
3 |
| Rappta Therapeutics Oy | 9 |
3 |
| Allergan, Inc. | 2347 |
2 |
| Bayer HealthCare LLC | 1353 |
2 |
| Amgen Inc. | 4076 |
2 |
| Abbvie Inc. | 1800 |
2 |
| Battelle Memorial Institute | 2492 |
2 |
| Chiesi Farmaceutici S.p.A. | 965 |
2 |
| Constellation Pharmaceuticals, Inc. | 213 |
2 |
| Eli Lilly and Company | 3848 |
2 |
| InterMune, Inc. | 57 |
2 |
| Suzhou Zelgen Biopharmaceutical Co., Ltd. | 13 |
2 |
| Cellestia Biotech AG | 19 |
2 |
| Glaxo Group Limited | 4063 |
1 |
| Glaxosmithkline LLC | 537 |
1 |
| Other owners | 53 |